Innovative Non-Invasive Therapy For Heart Recovery
Patient Candidates For EECP
Obstructive Coronary Artery Disease
Not readily amenable for intervention: symptomatic, obstructive CAD without a clear target to revascularize
Symptomatic Microvascular Disease
Exertional symptoms without obstructive lesions; Believed to be due to reduced flow in the microcirculation
Ischemic Heart Failure
Heart failure with underlying ischemia, regardless of ejection fraction. Continued symptoms despite medical therapy and at increased risk of hospitalization
We Make Patient Referrals Easy
Add to your cardiology care options with safe, durable, counterpulsation therapy.
Backed By Research
There are more than 430 peer-reviewed publications demonstrating the safety and efficacy of counterpulsation therapy. Read about the strong data supporting this innovative treatment modality.
Flow Therapy By The Numbers
40,000+
Every year, Flow Therapy performs 40,000+ EECP treatments.
Trusted
Trusted by providers at leading institutions like Mayo Clinic, Cleveland Clinic, and Johns Hopkins.
1,000+
Every year, more than 1000 clinicians refer their patients to Flow Therapy.
Lasting
Research shows that the benefits of EECP persist for 2-5 years post-treatment.
90%
90% of patients complete the full 35-session treatment course at Flow Therapy.
88%
88% of patients experience significant improvement of symptoms.
Covered
EECP Flow Therapy is FDA approved, and covered by Medicare and all commercial insurances.
91%
